B 2067
Alternative Names: B-2067Latest Information Update: 25 Jul 2022
At a glance
- Originator Tasly Biopharmaceuticals
- Class Bispecific antibodies; Eye disorder therapies
- Mechanism of Action Autoantibody inhibitors; Complement system protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Neuromyelitis optica